Camille Samuels

Camille Samuels General Information

Biography

Ms. Camille Samuels serves as a Partner at Venrock. She served as Board Member at Kythera Biopharmaceuticals and Biolux Research. She serves as a Board Member and Member of the Audit Committee at Unity Biotechnology. She serves as a Member of the board of directors at Ocelot Bio and Mahzi Therapeutics. She serves as Advisor at Mission Bay Capital. She served as Board Member at Corvidia & Spirox. She joined Venrock in 2014 and focuses on healthcare with an emphasis on biotech and consumer health. Prior to Venrock, she was a Managing Director at Versant Ventures for a decade where she led investments in Achaogen (AKAO), Kythera (KYTH), Novacardia (acquired by Merck), and ParAllele (acquired by Affymetrix), among others. She serves as Board Member at Iris Medicine. She was also a board observer at several companies including Genomic Health (GHDX), Fluidigm (FLDM), and Syrrx (acquired by Takeda). Before Versant, she was responsible for business development at Tularik, Inc. (acquired by Amgen) where she in-licensed two of the company's clinical-stage products and led Tularik's Technology Acquisition Group. Before Tularik, she worked in corporate development at Genzyme and Millennium Predictive Medicine and was a management consultant to healthcare and biotech companies at LEK Consulting. She earned her Bachelor's degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar.